Hyundai Bioscience

Name

Hyundai Bioscience

Legal name

Hyundai Bioscience Co., Ltd. (현대바이오사이언스 주식회사)

Website

https://hyundaibioscience.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Short description

Hyundai Bioscience is a South Korea-based clinical-stage biotechnology company developing broad-spectrum antivirals (XAFTY®), oncology therapeutics (Penetrium™, POLYTAXEL®), and cosmeceuticals (VITABRID CG) using proprietary drug delivery technology for global health authorities, government agencies, and premium skincare consumers.

Ownership category

akta.pro rank

Product category

Pharmaceutical drug delivery systems

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC)

Keywords

• Drug delivery systems
• Broad-spectrum antivirals
• Anticancer therapeutics
• Cosmeceutical products
• Pharmaceutical development

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical / Drug Development Revenue: Revenue from development and commercialization of proprietary drug candidates including XAFTY® (broad-spectrum antiviral), Penetrium™ (oncology/immuno-modulation), and POLYTAXEL® (anticancer). The company is in clinical development stage; revenue is nascent. FY2024 (25th period): 151 billion KRW consolidated revenue with 8 billion KRW operating profit; FY2025 (26th period): 35 billion KRW consolidated revenue, 182 billion KRW operating loss, 221 billion KRW net loss — with the decline attributed to absence of prior-year tech transaction revenue and increased R&D/clinical trial costs.
2. Cosmeceutical / Cosmetic Product Sales: Revenue from VITABRID C12 and related cosmetic products sold through multiple channels including Dr. Brid e-commerce store, Barneys New York (previously), exclusive Korea distribution with CMG Pharmaceutical, and export to Russia. Products include Vitabrid C12 SKIN (grand gold Monde Selection award winner), Vitabrid C12 HAIR (quasi-drug in Japan), and general cosmetics. One of the revenue contributors to FY2024 performance.
3. Technology Licensing and Manufacturing Partnerships: Revenue from technology licensing and manufacturing agreements with pharmaceutical partners. Includes: Production Partnership Agreement with Dongkook Pharmaceutical Co., Ltd.; Manufacturing Agreement with YOOYOUNG Pharm. Co., Ltd.; Exclusive Supply Agreement for Vitabrid C12 in Russia; and Exclusive Sales and Marketing Agreement in Korea with CMG Pharmaceutical for VITABRID C12.
4. Technology Transaction Revenue: One-time technology transfer or transaction revenue. FY2024 benefited from new technology transaction revenue that did not recur in FY2025, contributing to the significant revenue decline between periods. Nature of transactions not further detailed in public filings.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Core offering

Hyundai Bioscience develops proprietary drug delivery system (DDS) platforms based on organic-inorganic hybrid nanohybrids, polymer-based carriers, and Layered Double Hydroxide (LDH) technology. These platforms are applied to pharmaceutical drug candidates including XAFTY® (broad-spectrum antiviral CP-COV03 based on niclosamide), Penetrium™ (ECM-targeting oncology platform CP-PCA07), and POLYTAXEL® (polymer-based anticancer therapy). The company also produces the VITABRID C12 cosmeceutical line using the same LDH delivery technology.

Differentiator

Problem solved

Functional benefit

Brands

• XAFTY® (제프티): Broad-spectrum host-directed antiviral drug candidate based on niclosamide, targeting COVID-19, dengue, influenza, RSV, Ebola, and other viruses. Active ingredient is niclosamide, developed using proprietary drug delivery technology to overcome low bioavailability.
• Penetrium™
• POLYTAXEL®
• VITABRID CG / VITABRID C12
• Hyundai Bioscience USA
• Penetrium Bioscience Inc.

Products and services

• XAFTY® (CP-COV03) Host-directed broad-spectrum antiviral drug candidate based on niclosamide, delivered via proprietary DDS that improves bioavailability up to 40-fold. Demonstrates efficacy against 31+ viral families including COVID-19, Ebola, Dengue, Influenza, RSV, and Mpox. Developed for pandemic preparedness and emergency use authorization targeting global health authorities and healthcare providers.
• Penetrium™ (CP-PCA07) ECM-targeting immuno-oncology platform therapeutic that eliminates cancer-associated fibroblasts (CAFs) to normalize the tumor microenvironment and overcome pseudo-resistance. Restores responsiveness to chemotherapy, targeted therapy, and immunotherapy in solid tumors such as pancreatic and prostate cancer.
• POLYTAXEL® Polymer-based low-toxicity first-line anticancer therapy incorporating docetaxel into a polyphosphazene-based drug delivery system. Ultra-small (~10nm) nanoparticles enable delivery to hard-to-reach organs such as the pancreas; achieves up to ~44× higher NOAEL compared to conventional docetaxel, expanding the safe dosing range.
• VITABRID C12 Cosmeceutical product line including Vitabrid C12 SKIN, Vitabrid C12 HAIR, and related formulations that use Layered Double Hydroxide (LDH) carrier structure to stabilize high-purity vitamin C (>40%) and provide sustained release for over 12 hours. Registered as CTFA #10315. Targets premium skincare consumers seeking anti-aging and brightening benefits with pharmaceutical-grade DDS technology differentiation.

Quantifiable outcome

• XAFTY® demonstrated IC50 of 0.125μM against Ebola virus — more than double the inhibitory effect seen against SARS-CoV-2 (0.28μM), with established human safety from 300-person COVID-19 trial
• +5 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

13 partnerships are on record, tiered major, core and notable.

• WHO and African Country Health AuthoritiesmajorStrategic or Co-development Partner · 10 June 2026Hyundai Bioscience USA submitted official letter to WHO proposing deployment of XAFTY® under WHO's MEURI emergency-use framework for Ebola outbreak response in African countries. Company offered free drug supply and full funding for rapid clinical trials if required. Proposal following Dr. Davey Smith's recommendation based on strong in vitro Ebola data.
• BEPHARCO (Vietnam)coreStrategic or Co-development Partner · 7 May 2026MOU signed at 2026 Vietnam-Korea Economic Forum for cooperation on dengue clinical trials and potential dengue treatment market development in Vietnam. Vietnam's Ministry of Health approved XAFTY® dengue basket clinical trial IND application. BEPHARCO is a major Vietnamese pharmaceutical company.
• UC San Diego / Dr. Davey SmithmajorStrategic or Co-development Partner · 15 January 2026Dr. Davey Smith, Chief of Infectious Diseases at UC San Diego and former chair of U.S. government's ACTIV-2 COVID-19 trials, collaborated on clinical design for XAFTY® 'Basket Trial' approach. Proposed rapid deployment of XAFTY® for Ebola based on in vitro results and existing human safety data. Key opinion leader providing scientific endorsement for the broad-spectrum antiviral strategy.
• U.S. Department of Defense — Medical CBRN Defense Consortium (MCDC)coreStrategic or Co-development Partner · 1 September 2025Hyundai Bioscience USA granted full membership in the U.S. DoD Medical CBRN Defense Consortium (MCDC) — the first such approval for any Korea-affiliated company (2025). MCDC advances medical countermeasure R&D against chemical, biological, radiological, and nuclear threats. Following RRPV meeting, the company received additional TechWatch meeting invitation from DoD CBRN Medical division, signaling elevated policy and military cooperation status.
• BARDA / U.S. Department of Health and Human Services (HHS)majorStrategic or Co-development Partner · 1 August 2025BARDA (Biomedical Advanced Research and Development Authority) invited Hyundai Bioscience USA to present at RRPV (Rapid Response Partnership Vehicle) 2025 annual meeting — a U.S. government public-private partnership for public health emergency response. BARDA announced policy shift toward threat-agnostic, host-directed, broad-spectrum antiviral development, aligning directly with XAFTY® approach.
• Hyundai Bioscience USA Inc.coreOthers · 1 January 2025Wholly-owned U.S. subsidiary established in 2022 serving as the North American research and business development hub. Oversees clinical development, regulatory strategy, and partnerships for global antiviral and oncology pipelines. Achieved first-ever full membership in U.S. DoD Medical CBRN Defense Consortium (MCDC) for a Korean company in 2025. Key interface with U.S. government agencies (BARDA, NIH, DoD).
• U.S. NIH / NIAIDmajorStrategic or Co-development Partner · 1 January 2025Company announced building pandemic response systems with U.S. NIH. Engagement with NIAID for broad-spectrum antiviral development and evaluation. NIH's investment in next-generation pandemic response aligns with XAFTY® development strategy.
• Penetrium Bioscience Inc. (formerly ADM Korea Inc.)coreOthers · 1 January 2024Acquired in 2024 and renamed Penetrium Bioscience Inc. Operates as subsidiary focused on the Penetrium™ oncology platform. The acquisition expanded the company's oncology pipeline capabilities and clinical assets for pseudo-resistance therapeutics.
• Vietnam National Hospital of Tropical Diseases (NHTD)coreStrategic or Co-development Partner · 1 January 2024MOU signed in 2024 for collaboration on dengue clinical trials. NHTD is the primary collaborating institution for Vietnam Phase 2/3 dengue basket clinical trial of XAFTY® (Track 1 of 'One Drug, Two Tracks' strategy). Partnership extended in 2026 with BEPHARCO involvement at Vietnam-Korea economic forum.
• Dongkook Pharmaceutical Co., Ltd.coreImplementation/ SI/ Consulting Partner · 1 January 2022Production Partnership Agreement signed in 2022 for manufacturing/supply of CP-COV03 (XAFTY®). Dongkook Pharmaceutical, a established Korean pharma manufacturer, provides production capabilities to support clinical and potential commercial supply.
• YOOYOUNG Pharm. Co., Ltd.coreImplementation/ SI/ Consulting Partner · 1 January 2021Manufacturing Agreement signed in 2021 for production of CP-COV03 (XAFTY®). Provides dedicated manufacturing capacity for the antiviral drug candidate.
• CMG PharmaceuticalcoreChannel Partner/ Reseller/ Distributor · 1 January 2021Exclusive Sales and Marketing Agreement signed in 2021 for VITABRID C12 cosmeceutical products in the Korean market. CMG Pharmaceutical manages retail and pharmacy distribution of the Vitabrid CG-based cosmetic line within Korea.
• Barneys New York (U.S. Retail)notableChannel Partner/ Reseller/ Distributor · 1 January 2017Vitabrid C12 launched at 11 Barneys New York stores in the U.S. in 2017, making Hyundai Bioscience the first Korean brand to achieve retail placement at Barneys New York. Represented significant brand validation for the cosmeceutical line.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Emergent BioSolutions: Emergent BioSolutions is a larger biodefense and government-procured medical countermeasure company with established U.S. government contracts (similar to Hyundai Bioscience's MCDC positioning). Comparable customer base in U.S. DoD/HHS pandemic preparedness procurement and CBRN medical countermeasure market.
• SIGA Technologies: SIGA Technologies develops TPOXX (tecovirimat), a small-molecule antiviral for smallpox that is primarily procured by U.S. and allied governments for biodefense stockpiles. Highly comparable business model focused on government-procured antivirals for outbreak preparedness.
• Vir Biotechnology: Vir Biotechnology is a clinical-stage infectious disease company developing antibodies and small molecules for serious viral diseases including COVID-19, influenza, and hepatitis. Broader peer in the antiviral infectious disease space with established Big Pharma partnerships and more advanced pipeline.

Direct peers

• Cocrystal Pharma: Cocrystal Pharma is a small clinical-stage antiviral developer pursuing therapeutics for influenza, COVID-19, and norovirus. Comparable as a focused small-molecule antiviral clinical-stage peer with similar size and pipeline risk profile.
• Atea Pharmaceuticals: Atea Pharmaceuticals developed bemnifosbuvir, a small-molecule antiviral for COVID-19 and other RNA viruses. Direct comparable as a small-molecule clinical-stage antiviral developer with similar regulatory pathways and government health procurement customer profile.
• Arcturus Therapeutics: Arcturus Therapeutics develops lipid nanoparticle (LNP) drug delivery platforms for infectious disease vaccines and therapeutics. The technology overlap with Hyundai's polymer-based DDS and overlapping infectious disease focus (including respiratory viruses) make it a strong comparability match for delivery-platform-driven biotech.
• NanoViricides: NanoViricides develops polymer-based micelle therapeutics targeting viral infections, directly comparable to Hyundai Bioscience's polymer-based XAFTY broad-spectrum antiviral platform. Both are small clinical-stage biotechs using proprietary nanocarrier delivery to enable otherwise non-bioavailable drugs against multiple virus families.

Regional players

• Amorepacific: Amorepacific is a major Korean cosmeceutical and beauty company with global distribution. Comparable as a Korean cosmeceutical peer with established global retail presence (analogous to Hyundai Bioscience's Vitabrid C12 distribution via Barneys New York, Russia, Japan).
• Celltrion: Celltrion is a major Korean biosimilars and biotechnology company. While significantly larger, it serves as a relevant regional comparable for Korean biotech commercial infrastructure, KOSDAQ/KRX capital markets context, and global pharmaceutical distribution from Korea.
• SK Bioscience: SK Bioscience is a Korean vaccine and biotechnology company that supplies global health organizations including WHO and CEPI. Comparable regional peer with similar government procurement orientation and pandemic preparedness positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@hyundaibiocorp
• LinkedInlinkedin.com/company/hyundai-bioscience-co-ltd
• Instagraminstagram.com/dr.brid_official

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hyundai Bioscience